Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML). This updated analysis of the BELA trial assessed the safety profile and management of toxicities of bosutinib versus imat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambacorti-Passerini, Carlo, Cortes, Jorge E, Lipton, Jeff H, Dmoszynska, Anna, Wong, Raymond S, Rossiev, Victor, Pavlov, Dmitri, Gogat Marchant, Karin, Duvillié, Ladan, Khattry, Navin, Kantarjian, Hagop M, Brümmendorf, Tim H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305212/
https://www.ncbi.nlm.nih.gov/pubmed/24944159
http://dx.doi.org/10.1002/ajh.23788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305212/
https://www.ncbi.nlm.nih.gov/pubmed/24944159
http://dx.doi.org/10.1002/ajh.23788

Ejemplares similares